Barfresh Food Group And 2 Other US Penny Stocks To Consider

As the U.S. stock market navigates a mix of rising Treasury yields and fluctuating indices, investors are keenly observing opportunities for growth amid these dynamic conditions. Penny stocks, while often overlooked, remain an intriguing segment of the market. These stocks typically represent smaller or newer companies and can offer significant growth potential when supported by strong financial health and fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$99.16M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.36	$1.91B	★★★★☆☆
BAB (OTCPK:BABB)	$0.89	$6.46M	★★★★★★
Pangaea Logistics Solutions (NasdaqCM:PANL)	$4.84	$227.01M	★★★★★☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.2109	$7.76M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.84	$86.14M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$0.9694	$17.19M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.78	$70.15M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.51	$374.79M	★★★★☆☆

Click here to see the full list of 742 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Barfresh Food Group (NasdaqCM:BRFH)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Barfresh Food Group, Inc. manufactures and distributes ready-to-drink and ready-to-blend frozen beverages in the United States, with a market cap of $37.16 million.

Operations: The company's revenue is primarily derived from its non-alcoholic beverages segment, totaling $9.85 million.

Market Cap: $37.16M

Barfresh Food Group, Inc. has shown promising revenue growth, with third-quarter sales reaching US$3.64 million, a 40% increase from the previous year. Despite being unprofitable and having a negative return on equity of -190.59%, the company is reducing losses and forecasts a 29.19% annual revenue growth rate. Recent product launches like "Pop & Go"™ aim to bolster future revenues, particularly in the education sector. The company maintains more cash than debt and has reduced its debt-to-equity ratio significantly over five years but faces challenges with shareholder dilution and high share price volatility.

• Get an in-depth perspective on Barfresh Food Group's performance by reading our balance sheet health report here.
• Review our growth performance report to gain insights into Barfresh Food Group's future.

Franklin Wireless (NasdaqCM:FKWL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Franklin Wireless Corp. provides integrated wireless solutions in North America and Asia, with a market cap of $50.67 million.

Operations: The company generates revenue primarily from the sale of wireless access products, totaling $34.46 million.

Market Cap: $50.67M

Franklin Wireless Corp. has demonstrated resilience in its financial performance, reporting first-quarter sales of US$13.32 million, up from US$9.66 million the previous year, and achieving a net income of US$0.52 million compared to a loss last year. Despite being unprofitable over the past five years with increasing losses, the company remains debt-free and has stable weekly volatility at 4%. Recent product innovations like the JEXtream FX20 WiFi 6 router with Quvo parental controls highlight its commitment to enhancing digital safety and expanding market presence across various sectors such as elder care and small businesses.

• Take a closer look at Franklin Wireless' potential here in our financial health report.
• Learn about Franklin Wireless' historical performance here.

Shattuck Labs (NasdaqGS:STTK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and autoimmune diseases in the United States, with a market cap of $54.90 million.

Operations: The company generates revenue from its biotechnology segment, amounting to $6.44 million.

Market Cap: $54.9M

Shattuck Labs, Inc. is navigating the challenges of being a clinical-stage biotech company with a market cap of US$54.90 million and revenue of US$6.44 million. Despite its unprofitability, the company has strategically shifted focus to its SL-325 program, targeting autoimmune diseases with promising early results in monotherapy efficacy. Recent earnings show reduced losses compared to last year, indicating potential financial improvement. Shattuck's financial position is relatively stable with short-term assets covering liabilities and no debt burden; however, it faces increased share price volatility and limited cash runway if current expenditure trends persist without additional funding or revenue growth.

• Unlock comprehensive insights into our analysis of Shattuck Labs stock in this financial health report.
• Gain insights into Shattuck Labs' future direction by reviewing our growth report.

Where To Now?

• Take a closer look at our US Penny Stocks list of 742 companies by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com